SCHEMBL29660337

SCHEMBL29660337

CCOc1ccc(-c2nc(C(=O)OC(C)(C)C)c(C(=O)C3CC3)s2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 2/20 0.42
TP53 P04637 1/20 0.42
TRPM8 Q7Z2W7 5/20 0.41
PTPN11 Q06124 1/20 0.40
MAPT P10636 5/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HSP90AA1 P07900 1/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
GPR119 Q8TDV5 1/20 0.39
JAK1 P23458 3/20 0.39
CDC7 O00311 2/20 0.38
DBF4 Q9UBU7 2/20 0.38
TARBP2 Q15633 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PPARG P37231 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29660409 0.86 MAPT (0.46) KDM4EALDH1A1HSD17B10TP53TRPM8
SCHEMBL29660334 0.83 TARBP2 (0.44) KDM4EALDH1A1HSD17B10TP53TRPM8
SCHEMBL29660324 0.80 MAPT (0.42) KDM4EALDH1A1HSD17B10TP53PTPN11
SCHEMBL29660317 0.80 PTPN11 (0.44) KDM4EALDH1A1HSD17B10TP53TRPM8
SCHEMBL29660332 0.80 MMP13 (0.39) KDM4EALDH1A1HSD17B10TP53PTPN11
SCHEMBL29660340 0.78 MAPT (0.40) KDM4EALDH1A1HSD17B10TP53PTPN11
SCHEMBL29660360 0.78 TARBP2 (0.41) KDM4EALDH1A1HSD17B10TP53PTPN11
SCHEMBL29911091 0.77 MAPT (0.41) KDM4EALDH1A1HSD17B10TP53MAPT
SCHEMBL29660309 0.76 MAPT (0.43) KDM4EALDH1A1HSD17B10TP53MAPT
SCHEMBL29660299 0.76 HSD17B10 (0.40) KDM4EALDH1A1HSD17B10TP53TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289698-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-09-15 US disclosed
EP-4003955-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289698-A1 INHIBITORS OF HUMAN ATGL LIPC, LIPG, PNLIP KDM4E 3614/4885ALDH1A1 2464/4885HSD17B10 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.